BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics reports promising results from its Phase 2 study of Bria-IMT™, an innovative immunotherapy for advanced metastatic breast cancer, presented at ASCO 2024. The treatment has doubled Progression-Free Survival and improved Clinical Benefit Rates compared to historical data, demonstrating significant potential as a safe and effective option for patients resistant to current therapies. The clinical data underscores Bria-IMT™’s ability to activate the immune system against cancer without severe side effects.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
